☆ 4.2 Editorial Material

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

EXPERT OPINION ON PHARMACOTHERAPY (2019)

Get Full Text
Add to Collection

Journal

EXPERT OPINION ON PHARMACOTHERAPY
Volume 20, Issue 1, Pages 5-9

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2018.1543406

Keywords

HER2; breast cancer; adjuvant; metastatic; trastuzumab; pertuzumab; T-DM1; lapatinib; neratinib; chemotherapy

Categories

Pharmacology & Pharmacy

Funding

  1. Fondazione Piemontese per la Ricerca sul Cancro (FPRC) (onlus) 5 x 1000 fondi Ministero della Salute 2013
  2. Associazione Italiana per la Ricerca sul Cancro (AIRC) IG 2016 [19174]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.